Price$34.50+0.41 (+1.22%)
01:30 PM07:45 PM
News · 26 weeks77+100%
2026-01-182026-07-12
Mix3290d
- Insider21(66%)
- SEC Filings6(19%)
- Earnings3(9%)
- Other2(6%)
Latest news
25 items- INSIDERCEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,659,945 units (SEC Form 4) (for withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Fitzgerald Meghan exercised 10,000 shares at a strike of $8.80 and sold $349,000 worth of shares (10,000 units at $34.90) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident and Vant Chair Torti Frank covered exercise/tax liability with 40,310 shares, decreasing direct ownership by 0.30% to 13,536,202 units (SEC Form 4) to cover withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh covered exercise/tax liability with 46,878 shares, decreasing direct ownership by 0.25% to 18,630,739 units (SEC Form 4) to satisfy tax liability4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Epperly Melissa B, sold $610,252 worth of shares (17,750 units at $34.38) and exercised 17,750 shares at a strike of $4.46 (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Manchester Keith S sold $56,444,076 worth of shares (1,638,163 units at $34.46), decreasing direct ownership by 10% to 1,748,403 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Gold Daniel Allen sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector by Deputization Qvt Financial Lp sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form 144 filed by Roivant Sciences Ltd.144 - Roivant Sciences Ltd. (0001635088) (Subject)
- SECSEC Form 144 filed by Roivant Sciences Ltd.144 - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERPresident & CIO Sukhatme Mayukh exercised 1,000,000 shares at a strike of $3.85 and sold $34,105,000 worth of shares (1,000,000 units at $34.10) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85 and sold $6,631,268 worth of shares (200,000 units at $33.16) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCFO Pulik Richard covered exercise/tax liability with 2,129 shares, decreasing direct ownership by 0.76% to 276,420 units (SEC Form 4) to satisfy tax liability4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERChief Accounting Officer Humes Jennifer covered exercise/tax liability with 3,582 shares, decreasing direct ownership by 3% to 109,782 units (SEC Form 4) (for withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form S-8 filed by Roivant Sciences Ltd.S-8 - Roivant Sciences Ltd. (0001635088) (Filer)
- SECSEC Form 10-K filed by Roivant Sciences Ltd.10-K - Roivant Sciences Ltd. (0001635088) (Filer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business UpdateIMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026 Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in no
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- PRRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the confere
- PRImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant Immunova
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERSEC Form 4 filed by Venker Eric4 - Roivant Sciences Ltd. (0001635088) (Issuer)
ROIV FAQ
6 questionsWhat does Roivant Sciences Ltd. do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Where does ROIV stock trade?
Roivant Sciences Ltd. (ROIV) is listed on NASDAQ.What sector and industry is ROIV in?
Roivant Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ROIV?
Roivant Sciences Ltd. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Outperform with a $3500.00 price target on 2026-03-20. Recent price targets range from $1050.00 to $3500.00.What companies are similar to ROIV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ROIV side-by-side with any of them on Quantisnow.How can I track ROIV on Quantisnow?
Quantisnow aggregates Roivant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ROIV to receive live email and push alerts on every new disclosure.